fingolimod hydrochloride has been researched along with Inflammatory Bowel Diseases in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Abdollahi, M; Baeeri, M; Ghafour-Broujerdi, E; Gholami, M; Hassani, S; Mousavi, T; Rahimifard, M; Vakhshiteh, F | 1 |
| Bishayee, A; Lukina, E; McGowan, E; Sukocheva, OA | 1 |
| Danese, S; Furfaro, F; Vetrano, S | 1 |
| Panés, J; Salas, A | 1 |
| Maeda, S; Matsuki, N; Nakagawa, T; Nakazawa, M; Ohno, K; Yokoyama, N; Yonezawa, T | 1 |
| Bamias, G; Behrens, EH; Boyer, JD; Clark, D; Gima, L; González-Cabrera, P; Jedlicka, P; Karuppuchamy, T; Peach, R; Rivera-Nieves, J; Rosen, H; Sarkisyan, G; Scott, F; Veny, M | 1 |
| Hibi, T; Kanai, T; Watanabe, M | 1 |
| Andoh, A; Bamba, S; Deguchi, Y; Fujiyama, Y; Inatomi, O; Tsujikawa, T; Yagi, Y | 1 |
| Daniel, C; Geisslinger, G; Radeke, HH; Sartory, N; Stein, JM; Zahn, N | 1 |
3 review(s) available for fingolimod hydrochloride and Inflammatory Bowel Diseases
| Article | Year |
|---|---|
Sphingolipids as mediators of inflammation and novel therapeutic target in inflammatory bowel disease.
Topics: Animals; Anti-Inflammatory Agents; Fingolimod Hydrochloride; Humans; Inflammation; Inflammatory Bowel Diseases; Protein Kinase Inhibitors; Signal Transduction; Sphingolipids | 2020 |
Past, Present and Future of Therapeutic Interventions Targeting Leukocyte Trafficking in Inflammatory Bowel Disease.
Topics: Animals; Antibodies, Monoclonal, Humanized; Cell Adhesion Molecules; Cell Communication; Chemotaxis, Leukocyte; Endothelial Cells; Fingolimod Hydrochloride; Gastrointestinal Agents; Gastrointestinal Tract; Humans; Immunoglobulins; Immunosuppressive Agents; Indans; Inflammatory Bowel Diseases; Integrins; Intercellular Adhesion Molecule-1; Leukocytes; Lysophospholipids; Mucoproteins; Natalizumab; Oxadiazoles; Phosphorothioate Oligonucleotides; Receptors, Lysosphingolipid; Sphingosine | 2018 |
Systemically circulating colitogenic memory CD4+T cells may be an ideal target for the treatment of inflammatory bowel diseases.
Topics: CD4-Positive T-Lymphocytes; Colon; Fingolimod Hydrochloride; Humans; Immunologic Memory; Immunosuppressive Agents; Inflammatory Bowel Diseases; Leukapheresis; Propylene Glycols; Sphingosine | 2009 |
6 other study(ies) available for fingolimod hydrochloride and Inflammatory Bowel Diseases
| Article | Year |
|---|---|
Comparison of the safety and efficacy of fingolimod and tofacitinib in the zebrafish model of colitis.
Topics: Animals; Colitis; Fingolimod Hydrochloride; Inflammatory Bowel Diseases; Myeloid Differentiation Factor 88; Trinitrobenzenesulfonic Acid; Zebrafish | 2022 |
Targeting S1P in Inflammatory Bowel Disease: New Avenues for Modulating Intestinal Leukocyte Migration.
Topics: Animals; Camphanes; Cell Movement; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Indans; Inflammatory Bowel Diseases; Leukocytes; Lysophospholipids; Molecular Targeted Therapy; Oxadiazoles; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Sulfhydryl Compounds; Sulfonamides | 2018 |
Sphingosine-1-phosphate (S1P) signaling regulates the production of intestinal IgA and its potential role in the pathogenesis of canine inflammatory bowel disease.
Topics: Animals; Dog Diseases; Dogs; Feces; Fingolimod Hydrochloride; Gene Expression; Immunoglobulin A; Inflammatory Bowel Diseases; Intestines; Lysophospholipids; Male; Sphingosine; Sphingosine 1 Phosphate Receptor Modulators; Sphingosine-1-Phosphate Receptors | 2019 |
Sphingosine-1-phosphate receptor-1 (S1P
Topics: Animals; Cell Movement; Cells, Cultured; Colitis; Dendritic Cells; Dextran Sulfate; Disease Models, Animal; Endothelium; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunologic Memory; Indans; Inflammatory Bowel Diseases; Intestines; Lymphocytes; Mice; Mice, Inbred C57BL; Mice, Transgenic; Oxadiazoles; Receptors, Lysosphingolipid | 2017 |
The S1P receptor modulator FTY720 prevents the development of experimental colitis in mice.
Topics: Animals; CD4-Positive T-Lymphocytes; Cell Transplantation; Colitis; Disease Models, Animal; Fingolimod Hydrochloride; Immunosuppressive Agents; Inflammatory Bowel Diseases; L-Selectin; Male; Mice; Mice, Inbred BALB C; Mice, SCID; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Spleen | 2006 |
FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells.
Topics: Animals; Antigens, CD; Antigens, Differentiation; Aziridines; Cell Differentiation; Choline; Colitis; CTLA-4 Antigen; Cytokines; Disease Models, Animal; Down-Regulation; Fingolimod Hydrochloride; Forkhead Transcription Factors; Immunosuppressive Agents; Inflammation; Inflammatory Bowel Diseases; Intestinal Mucosa; Male; Mice; Mice, Inbred BALB C; Neuromuscular Blocking Agents; Propylene Glycols; Sphingosine; T-Lymphocytes, Regulatory; Th1 Cells | 2007 |